Barclays raised the firm's price target on Altria Group to $64 from $63 and keeps an Underweight rating on the shares. The firm thinks there will be increased innovation in the tobacco sector following the latest FDA guidance, which could lead to faster next-generation products growth and drive a re-rating of the stocks.
